

# Site Alliances

## The Power of Site Engagement | Oncology


Now more than ever, early engagement with experienced sites is critical to the success of any protocol – especially in oncology trials. That's why, here at Worldwide Clinical Trials, we created the Site Alliance Collaboration, not just targeting major academic centers, but all types of sites in order to deliver the most efficient trials for our clients.

### What Does This Mean For Your Trial?

- Real principal investigator (PI) feedback on your protocol
- Increased awareness for your product in competitive markets
- Expedited feasibility process for quicker selection
- Opportunity to leverage existing relationship structure with Alliance sites

### Wondering When to Begin Engaging With Sites?

- **Are you unsure about how your protocol design or inclusion/exclusion criteria will impact potential enrollment goals?**  
Our Alliance sites, under mCDA, proactively review protocols during development to evaluate enrollment feasibility and advise you of any hurdles created by the protocol design or criteria.
- **Is your targeted indication already crowded with trials competing for a similar patient population?**  
Working closely with our KOLs and expert PIs from the Alliance sites can give your protocol or program the necessary exposure and create interest ahead of the competition. This is especially valuable if the competing trials are for highly visible or well-established sponsors.
- **Would you like to be more confident in your country mix selections?**  
Our Alliance sites across the USA, Europe, and Australia can typically confirm their patient populations and feasibility of a protocol within their country within two to five business days of an unblinded request. Since we already have existing relationships built on transparency, our Alliance sites are more likely to be candid about which protocols are not suitable for their patients, rather than just taking a trial but never enrolling.
- **Are you worried about meeting First Patient In goals because of a tight start-up timeline?**  
One of the best ways to meet expedited start-up timelines is to engage as early as possible with our Alliance sites. The earlier sites can confirm interest, secure resourcing availability for a trial, and provide input into the timelines, the more we can increase the probability of meeting your FPI goals.



*"Investigators have become more selective on which protocols they accept due to limited resources and protocols becoming more targeted towards certain patient populations. This is why engaging earlier in the process with key Investigators can help sponsors understand these constraints when there is still time to positively impact the protocol and ensure we are targeting the right sites. At Worldwide, we have the expertise in rare genetic diseases and rare oncology studies to help you navigate this evolving landscape."*

**Scott Palmese**

Executive Director, Site  
relationship & DCT Solutions

